Cargando…

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma

Prognoses for patients with metastatic urothelial carcinoma (mUC) have improved with pembrolizumab treatment, an immune checkpoint inhibitor, but clinical benefits are limited to a subset of patients. Therefore, a non-invasive biomarker to predict pembrolizumab response is required. The present stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamada, Kazuki, Nagumo, Yoshiyuki, Kandori, Shuya, Tanuma, Kozaburo, Shiga, Masanobu, Hoshi, Akio, Negoro, Hiromitsu, Kojima, Takahiro, Mathis, Bryan J., Nishiyama, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407860/ https://www.ncbi.nlm.nih.gov/pubmed/37559592 http://dx.doi.org/10.3892/ol.2023.13975

Ejemplares similares

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
por: Isoda, Bunpei, et al.
Publicado: (2023)

Whole-Blood Gene Expression Profiles Correlate with Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Carcinoma
por: Nagumo, Yoshiyuki, et al.
Publicado: (2022)

ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma
por: Tanaka, Ken, et al.
Publicado: (2022)

Glucocorticoids coordinate the bladder peripheral clock and diurnal micturition pattern in mice
por: Chihara, Ichiro, et al.
Publicado: (2023)

Laparoendoscopic single‐site surgery for urachal remnant with extraperitoneal approach through a suprapubic port
por: Hoshi, Akio, et al.
Publicado: (2022)

Case Report: Molecular Characterization of Aggressive Malignant Retroperitoneal Solitary Fibrous Tumor: A Case Study
por: Nonaka, Haruna, et al.
Publicado: (2021)

ELOVL5‐mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma
por: Nitta, Satoshi, et al.
Publicado: (2022)

Retroperitoneal lymph node dissection for testicular cancer in a patient with a double inferior vena cava
por: Yamaguchi, Akane, et al.
Publicado: (2021)

Granulocyte colony‐stimulating factor associated arteritis in a patient with castration‐resistant prostate cancer
por: Nitta, Satoshi, et al.
Publicado: (2021)

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
por: Kobayashi, Takashi, et al.
Publicado: (2020)

TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer
por: Kawahara, Takashi, et al.
Publicado: (2019)

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors
por: Kawahara, Takashi, et al.
Publicado: (2022)

Impact of Early Exposure to Simulation Program on Undergraduate Medical Students’ Interest in Urology
por: Kimura, Tomokazu, et al.
Publicado: (2021)

Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
por: Hasegawa, Moto, et al.
Publicado: (2020)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
por: Nishiyama, Hiroyuki, et al.
Publicado: (2023)

Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model
por: Yoshino, Takayuki, et al.
Publicado: (2019)

Chronoradiation Therapy for Prostate Cancer: Morning Proton Beam Therapy Ameliorates Worsening Lower Urinary Tract Symptoms
por: Negoro, Hiromitsu, et al.
Publicado: (2020)

Bmal1 Regulates Prostate Growth via Cell-Cycle Modulation
por: Ueda, Masakatsu, et al.
Publicado: (2022)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
por: Ito, Katsuhiro, et al.
Publicado: (2022)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort
por: Ito, Katsuhiro, et al.
Publicado: (2021)

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report
por: Ding, Xinjia, et al.
Publicado: (2021)

Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples
por: Kurobe, Masahiro, et al.
Publicado: (2016)

Pannexin 1 Channels Play Essential Roles in Urothelial Mechanotransduction and Intercellular Signaling
por: Negoro, Hiromitsu, et al.
Publicado: (2014)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
por: McNally, Michelle A., et al.
Publicado: (2021)

Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma
por: Teshima, Taro, et al.
Publicado: (2022)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease
por: Li, Quanyi, et al.
Publicado: (2004)

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival
por: Nakamori, Keita, et al.
Publicado: (2022)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
por: Crist, Michael, et al.
Publicado: (2019)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
por: Rijnders, Maud, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s5634aql5nlni03uc2b2hhf4r7